清肺合剂联合GP方案治疗晚期非小细胞肺癌临床疗效观察

Clinical Effects of Qingfei Mixture Combined with Chemotherapy of GP Regimen in Treating Patients with Advanced Non-Small Cell Lung Cancer

目的:观察清肺合剂联合化疗治疗晚期非小细胞肺癌(NSCLC)临床疗效。方法:选择2008年1月-2010年1月间收治的经确诊的初治晚期NSCLC患者210例,分别入清肺合剂联合GP方案(治疗组)104例和单纯GP方案化疗(对照组)106例,入组患者至少接受2个周期以上的化疗。结果:入组的210例患者均可评价疗效,治疗1年后随访210例,治疗组99例,对照组98例,失访13例。治疗组和对照组总有效率分别是26.92%和19.81%,中位生存期为15.7个月和14.8个月,1年生存率为63.64%和55.10%。两组差异无显著性(P>0.05)。治疗后,治疗组在KPS评分、临床症状改善及化疗不良反应方面与对照组比较差异有统计学意义(P<0.05)。结论:清肺合剂联合化疗治疗晚期非小细胞肺癌,在改善患者的临床症状,提高患者的生活质量,减轻化疗的不良反应等方面具有临床意义。

Objective： To observe the effects of Qingfei Mixture in association with chemotherapy in curing patients with advanced non-small cell lung cancer（NSCLC）.Methods：Two hundreds and ten patients with confimed diagnosis of advanced non-small cell lung cancer between January 2008 and January 2010,were assigned to treatment group（Qingfei Mixture treatment combined with chemotherepy of GP regimen,n=104）and control group（chemotherepy of GP regimen,n=106）.All eligible patients received two cycles chemotherapy at least.Results：210 patients were evaluated for efficacy.The effective rate was 26.92% vs 19.81% in the treatment group and the control group respectively,median overal survival（OS）was 15.7months vs 14.8months,1-year survival was 63.64% vs 55.10%,but there were no significant differences between two groups（P0.05）.However,the KPS score,clinical symptom improvement and chemotherapy toxicity in the treatment group had statistical significance differences compared with those in the control group（P0.05）.Conclusion：Qingfei Mixture can improve clinical symptoms,enhance the quality of life and relieve side and toxic effects in treatment advanced NSCLC.